nexstim

Data Safety Monitoring Board recommends continuation of Nexstim Plc’s Phase III Stroke Therapy Trial

on 26/09/2015 17:13
Interim data analysis by an independent Data Safety Monitoring Board shows that safety criteria are met and trial should continue without any modifications
Read more

Nexstim: Key Technology Patent Granted for US

on 11/08/2015 15:52
Strengthened patent estate around Nexstim’s cutting-edge technology
Read more

Nexstim Navigated Brain Stimulation results to be presented at the German Society of Neurosurgery’s 66th Annual Meeting

on 09/06/2015 11:35
- 22 papers presented on pre-surgical mapping using Navigated Brain Stimulation - Significant validation for technology currently in Phase III study for stroke therapy
Read more

Nexstim adds Chronic Neuropathic Pain Therapy to its clinical indication pipeline with co-operation agreement with the Walton Center

on 16/12/2014 16:53
Nexstim announces a co-operation agreement with The Walton Centre
Read more

Nexstim Plc successfully completes its Initial Public Offering - subscriptions reach € 15.3 million with final offer price of € 6.35 per share

on 04/11/2014 15:37